Atlas Trials

Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma

Clinical trial NCT05373901 · COMPLETED

Trial details

NCT number
NCT05373901
Sponsor
BeiGene
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
High-risk Neuroblastoma
Start date
2022-06-07
Primary completion
2023-06-29
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.